Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

FDA Experts to Review Safety of Essure Birth Control Implant

September 22, 2015 12:20 pm | by Matthew Perrone, AP Health Writer | News | Comments

Federal medical experts will take a closer look at a host of problems reported with the birth control implant called Essure, including chronic pain, bleeding, headaches and allergic reactions. Read more...


Tuberculosis Drug's Big Price Hike is Revoked by Rodelis Therapeutics

September 22, 2015 11:15 am | by Stephanie Guzowski, Editor | News | Comments

A significant price increase for a specialty tuberculosis drug was rescinded Monday after the company that acquired the drug’s rights returned it to its previous owner, following public outrage. Rodelis Therapeutics acquired the rights to cycloserine last month, and raised its price 2,600 percent, from $500 for 30 capsules to $10,800. Read more...


Global HBV Therapeutics Market Value to Grow Slowly to $3.5B by 2021

September 22, 2015 8:31 am | by Priyatham Salimadugu, Analyst, GBI Research | News | Comments

The global late-stage pipeline is weak due to the lack of first-in-class and innovative products in late-stage clinical development. Read more...


Role of Cancer-Suppressing Gene Uncovered

September 22, 2015 8:25 am | by University of Adelaide | News | Comments

Researchers have uncovered the role played by a gene which suppresses the development of cancer. Read more...


Old Drug Performs New Tricks

September 22, 2015 7:45 am | by University of Cambridge | News | Comments

Patients with the most dangerous type of high blood pressure will be able to receive far more effective treatment after Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years. Read more...


Mylan Launches One of First Generic Lescol XL Tablets

September 22, 2015 7:30 am | News | Comments

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Read more...

Targeting DNA

September 22, 2015 7:15 am | by Anne Trafton, MIT News Office | News | Comments

MIT biological engineers have developed a modular system of proteins that can detect a particular DNA sequence in a cell and then trigger a specific response. Read more...


Bungling by U.N. Agency Hurt Ebola Response

September 22, 2015 7:00 am | by Maria Cheng, Raphael Satter, and Krista Larson, Associated Press | News | Comments

As a worker at Kenema Government Hospital mixed a batch of chlorine on a broiling August day, he noticed it didn't have its typically strong, bleach-like odor. Concerned, he turned to a consultant with the World Health Organization, who tested the disinfectant and found barely any active ingredient. Read more...


Merck: Phase 3 Studies of Bezlotoxumab to Prevent Clostridium Difficile Infection Recurrence

September 21, 2015 12:34 pm | News | Comments

Merck  today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence, met their primary efficacy endpoint: the reduction in C. difficile recurrence through week 12 compared to placebo, when used in conjunction with standard of care antibiotics for the treatment of C. difficile. Read more...


Gilead: Results from Four Phase 3 Studies Evaluating Hepatitis C Combination

September 21, 2015 12:25 pm | News | Comments

Gilead Sciences, Inc. today announced topline results from four international Phase 3 clinical studies (ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4) evaluating a once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) with velpatasvir (VEL), an investigational pangenotypic NS5A inhibitor, for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection.  Read more...


Clinton To Propose New Prescription Drug Proposal This Week

September 21, 2015 12:20 pm | by Associated Press | News | Comments

Hillary Rodham Clinton says she'll soon roll out a proposal for controlling the cost of prescription drugs, a key fix to President Barack Obama's signature health care law. Read more...


FDA Grants Priority Review for Amgen's Supplemental NDA in Relapsed Multiple Myeloma

September 21, 2015 12:15 pm | News | Comments

Amgen today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental New Drug Application (sNDA) of Kyprolis (carfilzomib) for Injection for patients with relapsed multiple myeloma.  Read more...


Vaccine Clears Some Precancerous Cervical Lesions in Clinical Trial

September 21, 2015 12:11 pm | by Johns Hopkins University | News | Comments

Scientists have used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial. The goal, say the scientists, was to find nonsurgical ways to treat precancerous lesions caused by HPV. Read more...


Rare Disease Drug Price Skyrockets, from $13.50 a Tablet to $750

September 21, 2015 11:30 am | by Stephanie Guzowski, Editor | News | Comments

A drug that is the standard of care for treating a life-threatening parasitic infection recently increased in price from $13.50 per pill to $750 — a nearly 5,000 percent jump. Read more...


U.S. Officials to Stop Screening Liberian Passengers for Ebola

September 21, 2015 8:15 am | by Mike Stobbe, AP Medical Writer | News | Comments

Travelers entering the U.S. from Liberia will no longer be screened for Ebola. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.